Scholarlink

<p>Ischemic mitral regurgitation (IMR) commonly complicates pPCI in STEMI patients. GDF11, a protective cardiovascular factor, may influence IMR progression and prognosis. Among 310 STEMI patients, 126 with recent normal echocardiography underwent pPCI with pre-procedural GDF11 testing. Cox regression, ROC analysis, and Spearman’s correlation assessed GDF11’s predictive value for IMR exacerbation and cardiac function. Lower GDF11 predicted IMR worsening (HR = 0.982, <i>P</i> = 0.004; AUC = 0.744, <i>P</i> &lt; 0.001). High GDF11 patients had reduced IMR progression (<i>P</i> = 0.0013) and heart failure risk (P = 0.0003). GDF11 correlated with LVEF and left atrial changes (<i>P</i> &lt; 0.05). Serum GDF11 independently predicts IMR exacerbation and post-pPCI heart failure, serving as a prognostic biomarker in STEMI.</p> Graphical Abstract <p>Serum GDF11 predicts IMR progression and heart failure prognosis in STEMI patients.</p> <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Correlation Between Serum GDF11 Levels and the Progression of Ischemic Mitral Regurgitation and Long-term Prognosis in Patients with ST-segment Elevation Myocardial Infarction After Percutaneous Coronary Intervention

  • 期刊论文

  • 发表日期：

    2026年2月5日

查看全文
  • Jiangping Ye,
  • Kewei Zong,
  • Yehong Liu,
  • Weijian Wang,
  • Ying Sheng,
  • Jie Liu,
  • Dongmei An,
  • Baida Xu,
  • Gangjun Zong

摘要

Ischemic mitral regurgitation (IMR) commonly complicates pPCI in STEMI patients. GDF11, a protective cardiovascular factor, may influence IMR progression and prognosis. Among 310 STEMI patients, 126 with recent normal echocardiography underwent pPCI with pre-procedural GDF11 testing. Cox regression, ROC analysis, and Spearman’s correlation assessed GDF11’s predictive value for IMR exacerbation and cardiac function. Lower GDF11 predicted IMR worsening (HR = 0.982, P = 0.004; AUC = 0.744, P < 0.001). High GDF11 patients had reduced IMR progression (P = 0.0013) and heart failure risk (P = 0.0003). GDF11 correlated with LVEF and left atrial changes (P < 0.05). Serum GDF11 independently predicts IMR exacerbation and post-pPCI heart failure, serving as a prognostic biomarker in STEMI.

Graphical Abstract

Serum GDF11 predicts IMR progression and heart failure prognosis in STEMI patients.